 Quetiapine is FDA approved in adults for treating manic symptoms associated with type I bipolar disorder, and evidence has shown that atypical anti-psychotics may have a role in therapy for children and adolescents.  Quetiapine has been shown to be as effective as divalproex monotherapy and the combination of the two medications was more effective than divalproex alone for treatment of acute bipolar mania in adolescents.
-9.04 (SE=1.12; 95% CI, -11.24 to -6.84) with placebo (p<0.001 each quetiapine dose vs. placebo).  Secondary Outcome Measures: Quetiapine was associated with significantly greater remission rates than placebo and significant improvements in CGI-BP Severity of Illness score vs. placebo (p=0.005 and p<0.001), respectively. Results were also statistically significant for achieving "very much improved" or "much improved" compared to baseline for CGI-BP Global Improvement. Changes in CGAS total score were statistically significant in both quetiapine treatment groups (p<0.05 and p<0.001), respectively. Differences in the Overt Aggression Scale and Caregiver Strain questionnaire were not statistically significant. Adverse effects were reported more frequently in quetiapine groups than placebo, and most commonly included somnolence, sedation, dizziness, and headache. The most frequently reported serious adverse event was exacerbation of bipolar disorder. Mean changes from baseline to final visit in pulse rate, ALT/AST, fasting glucose, total and LDL cholesterol, triglycerides, TSH, and prolactin levels were greater in the quetiapine groups than placebo, although no p-values were reported.  Author's conclusion: Quetiapine 400 mg/d or 600 mg/d were effective and well tolerated in children and adolescents for manic symptoms associated with type I bipolar disorder.
Strengths:
 Stratification by age allowed comparisons between ages 10-12 and 13-17  Patients with co-morbid ADHD were included  Bipolar disorder is commonly diagnosed at the age included in patient population
Limitations:
 Other types of bipolar disorder and co-morbid psychological disorders were excluded.  Short study duration  Unblinding was likely due to the adverse effect profile of quetiapine.  Non-flexible dosing protocol was used  Many factors left up to investigators' discretion, including washout period, daily dosing schedule, and the relation of adverse effects to study medication.
Conclusion:
 Quetiapine was effective compared to placebo in adolescents and children; however, it is not without risk. The potential long-term risks are unclear due to the short study duration. Quetiapine should be used cautiously in children, especially those ages 10-12. Children should be closely monitored for adverse effects including exacerbation of bipolar illness, suicide behavior, and unfavorable metabolic effects.  Studies are needed to evaluate the long term efficacy and safety of quetiapine in adolescents and children with bipolar type I disorder, and in children with other types of bipolar disorder or with other co-morbid psychological disorders.
